Gates Foundation Strategic Investment Fund Logo
Share this page:


Atreca is a biotechnology company that employs its proprietary discovery platform to generate and develop therapeutics based on its ability to rapidly characterize the human adaptive immune response at the single cell level.  The Atreca platform enables the high-throughput phylogenetic and functional analysis of native antibodies generated by human immune responses and has been used by foundation partners to isolate novel human monoclonal antibodies, provide novel insights into immune responses and vaccination, and generate new tools for global health vaccine discovery and development.  Atreca continues to discover and develop a pipeline of proprietary oncology immunotherapeutics based on the novel antibody-target pairs generated by its platform

News Story